Brokerages Set Horizon Pharma PLC PT at $37.88 (NASDAQ:HZNP)

Brokerages Set Horizon Pharma PLC PT at $37.88 (NASDAQ:HZNP)

Horizon Pharma PLC (NASDAQof “Buy” from the eleven research firms that are presently covering the stock, MarketBeat.Com reports. Two analysts have rated the stock with a hold rating and nine have issued a buy rating on the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $37.88.

Shares of Horizon Pharma PLC (NASDAQ:HZNP) opened at 17.06 on Thursday. The stock’s market capitalization is $2.72 billion. The company’s 50-day moving average price is $22.48 and its 200 day moving average price is $29.63. Horizon Pharma PLC has a one year low of $11.87 and a one year high of $39.49.

Horizon Pharma logoHorizon Pharma PLC (NASDAQ:HZNP) last posted its quarterly earnings data on Friday, August 7th. The biopharmaceutical company reported $0.39 EPS for the quarter, topping the consensus estimate of $0.32 by $0.07. During the same period last year, the business earned $0.21 EPS. The company earned $172.80 million during the quarter, compared to the consensus estimate of $156.41 million. The firm’s quarterly revenue was up 161.4% compared to the same quarter last year. Analysts anticipate that Horizon Pharma PLC will post $1.39 EPS for the current year.

pills23In other Horizon Pharma PLC news, EVP Jeffrey W. Sherman sold 7,750 shares of Horizon Pharma PLC stock in a transaction that occurred on Monday, September 21st. The shares were sold at an average price of $31.78, for a total transaction of $246,295.00. Following the completion of the sale, the executive vice president now directly owns 105,132 shares in the company, valued at approximately $3,341,094.96. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

HZNP has been the topic of several recent research reports. Leerink Swann reiterated a “positive” rating and set a $37.00 target price on shares of Horizon Pharma PLC in a research report on Tuesday, July 7th. Brean Capital restated a “buy” rating and set a $40.00 price target (up previously from $33.00) on shares of Horizon Pharma PLC in a report on Wednesday, July 8th. Piper Jaffray reiterated a “positive” rating and issued a $38.00 target price on shares of Horizon Pharma PLC in a report on Tuesday, July 14th. Guggenheim restated a “buy” rating on shares of Horizon Pharma PLC in a report on Monday, August 3rd. Finally, JMP Securities started coverage on Horizon Pharma PLC in a research report on Wednesday, September 9th. They set an “outperform” rating and a $39.00 target price for the company.

Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a specialty biopharmaceutical firm focused on identifying, developing, acquiring or in- commercializing and licensing differentiated products that address unmet medical needs. The Company markets a portfolio of products in orphan and arthritis, inflammation disorders. The Company’s the United States advertised products are ACTIMMUNE (NASDAQ:HZNP), DUEXIS (ibuprofen/famotidine), PENNSAID (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%), RAYOS (prednisone) delayed-release pills and VIMOVO (naproxen/esomeprazole magnesium). The Company developed DUEXIS and RAYOS/LODOTRA, gets the Usa rights to VIMOVO, gets the Usa rights and has the Usa rights to PENNSAID 2%.

marketbeat-logo.pngFor more information:

Disclaimer/ Disclosure: The Investors News Magazine is a third party publisher of news and research as well as creates original content as a news source. Original content created by Investors News Magazine is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site may be compensated by featured companies for news submissions and content marketing. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s